MedTrace Logo

Albumin Administration and Outcomes in Cardiac Surgery

NCT02878733 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6249

Last updated 2016-08-25

No results posted yet for this study

Summary

The invesitgators utilized the Cerner HealthFacts database (a large HIPAA-compliant clinical-administrative database maintained by Cerner Inc., USA) to identify a cohort of 6,249 adults that underwent on-pump cardiac surgery for valve and/or coronary artery procedures between January 2001 and March 2013. Of these, the investigators selected 1136 patients who received 5% albumin on the day of or the day following cardiac surgery and matched them (1:1) with 1136 patients who did not receive albumin. Characteristics on which patients were matched included patient demographic, hospital and procedural characteristics, baseline patient comorbidities including preoperative CKD and 26 other grouped conditions, as well as acute severity of illness at admission to ICU.

Conditions

  • Thoracic Surgery

Interventions

DRUG

Albumin

patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Grifols Biologicals, LLC

    collaborator INDUSTRY

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Adam kingeter, MD · Vanderbilt University Medical Center

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02878733 on ClinicalTrials.gov